Description:Regorafenib hydrate is a small-molecule tyrosine kinase inhibitor primarily used in the treatment of various cancers, including colorectal cancer and gastrointestinal stromal tumors. It functions by inhibiting multiple kinases involved in tumor growth and angiogenesis, thereby disrupting the signaling pathways that promote cancer progression. The substance is characterized by its complex structure, which includes a pyridine ring and a phenyl group, contributing to its pharmacological activity. Regorafenib hydrate is typically administered orally and is known for its moderate solubility in water, which is enhanced in its hydrate form. The hydrate form is significant as it can influence the drug's stability, solubility, and bioavailability. Common side effects associated with regorafenib include fatigue, diarrhea, and hypertension, reflecting its systemic effects on both cancer cells and normal tissues. As with many targeted therapies, careful monitoring is essential to manage potential adverse effects and ensure optimal therapeutic outcomes.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyri…](https://static.cymitquimica.com/products/IN/thumb/DA008TJC.jpg)
